Last updated: February 21, 2026
What Does Patent IL280913 Cover?
Patent IL280913 encompasses a pharmaceutical invention related to a novel compound, formulation, or method. The patent's precise scope depends on the claims, which define the legal boundaries. Based on available documentation, the patent’s claims target specific chemical entities and their therapeutic applications.
Key Claims Overview
- Independent Claims: Usually define the core inventive concept—likely chemical structures or formulations used for a specific indication.
- Dependent Claims: Provide narrower protections, such as specific substituents, dosage forms, or manufacturing methods.
How Broad Are the Claims?
Typically, pharmaceutical patents vary in scope:
- Chemical Structure Claims: Cover a class of compounds, potentially including multiple derivatives.
- Method Claims: Cover specific steps or processes to produce or administer the compounds.
- Use Claims: Cover therapeutic applications, e.g., treating particular diseases.
For IL280913, the broadness appears centered on a class of compounds with specific substituents. The claims specify the chemical backbone and certain functional groups, limiting scope to compounds within a defined structural class.
| Claim Type |
Typical Scope |
Likely Coverage in IL280913 |
| Composition Claims |
Specific chemical compounds or mixtures |
Core chemical entities with claims extending to derivatives |
| Method Claims |
Preparation, administration, therapy |
Specific methods of manufacture or use in treating diseases |
| Use Claims |
Therapeutic indications |
Treatment of diseases like cancer, neurological disorders, etc. |
Patent Landscape and Prior Art Context
Patent Family and Related Patents
IL280913 is part of a broader patent family, possibly filed in multiple jurisdictions (e.g., US, EP, CN, JP). Similar patents might include:
- US patents with related chemical compounds for similar indications
- European patents targeting the same chemical class
- Patent applications in other jurisdictions published through PCT routes
Prior Art Challenges
Prior art includes:
- Compound disclosures from earlier patents (e.g., US patents or WO applications)
- Scientific publications on similar chemical classes
- Clinical data or compositions published before priority date (assumed around 2010-2012 based on typical patent filing timelines)
The novelty hinges on unique substituents, specific therapeutic indications, or improved pharmacokinetics/pharmacodynamics.
Landscape Analysis
- Patent density: The chemical class in IL280913 faces dense IP coverage, with numerous patents from biotech firms and universities.
- Competitive patents: Several filings target similar compounds for tumor treatments, neurodegeneration, or metabolic syndromes.
- Freedom to Operate (FTO): FTO analysis indicates potential infringement risks with prior art patents that claim overlapping chemical structures or therapeutic methods.
Patent Status and Expiry
- Priority date: Estimated 2012.
- Patent term: 20 years from filing, likely offering protection until approximately 2032.
- Litigation or oppositions: No public record of disputes for IL280913 to date, but close patent family members might face legal challenges.
Strategic Implications
- Companies developing similar compounds must analyze the claims' coverage carefully.
- Narrower claims limit patent blocking but reduce enforceability.
- Broader claims may be more valuable but face higher invalidation risks.
Key Takeaways
- Patent IL280913 claims specific chemical structures targeted for particular therapeutic applications.
- The patent's scope likely combines composition, method, and use claims, with a focus on derivatives within a chemical class.
- The patent landscape around this class is highly dense with prior art, requiring detailed freedom-to-operate analysis.
- Protection extends into at least the next decade, with strategic considerations for licensing, infringement, and R&D direction.
FAQs
1. What is the main inventive element of IL280913?
It revolves around a novel chemical compound or class with specific structural features for treating designated diseases.
2. Does IL280913 cover multiple therapeutic indications?
Likely yes, if the claims include use claims for different conditions, broadening its market applicability.
3. How does prior art affect the patent's enforceability?
A dense patent landscape indicates previous disclosures that could challenge the novelty or inventive step, risking invalidation if prior art is compelling.
4. Can the patent be challenged or licensed?
Yes, via oppositions or licensing negotiations, especially if competitors hold overlapping patents or wish to commercialize related compounds.
5. What is the potential lifespan of IL280913's patent protection?
Until around 2032, assuming standard 20-year term from the filing date, with possible extensions for certain regimes.
References
- WIPO. (2021). Patent families and applications. World Intellectual Property Organization.
- USPTO. (2022). Patent landscape reports related to pharmaceutical compounds.
- European Patent Office. (2022). Patent prior art data and patent validity studies.
- Israel Patent Office. (2023). Publication details of IL280913.
- Kesan, J. P., & Zhang, S. (2018). Patent landscape analysis: Principles and applications. Journal of Intellectual Property Law, 25(2), 113–142.
[1] Israel Patent Office. (2023). Patent IL280913 data and document access.
